Transparency notification BlackRock, Inc.

Brussels (Belgium), 21 August 2024 – 20:00 (CEST) – Regulated information 

1.  Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from BlackRock, Inc. (having its registered office at 50 Hudson Yards, New York, NY, 10001, U.S.A.), dated 16 August 2024. 
BlackRock, Inc. notified that, following an acquisition of UCB shares with voting rights or assimilated instruments by its affiliates, its shareholding in UCB SA increased and crossed the 5% threshold on 15 August 2024.
On 15 August 2024, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 745 869 UCB shares with voting rights or assimilated instruments, representing 5,01% of the total number of shares issued by the company (194 505 658), versus 4,84% (9 412 691 UCB shares) in the previous notification dated 14 January 2020.

2.  Content of the notification
 

• Reason for the notification: Acquisition or disposal of voting securities or voting rights, acquisition or disposal of financial instruments that are treated as voting securities.
   
• Notification by: A parent undertaking or a controlling person.
   
• Persons subject to the notification requirement:

• Date on which the threshold is crossed: 15 August 2024.
   
• Threshold crossed (in %): 5%.
   
• Denominator: 194 505 658.
   
• Notified details:

• Chain of controlled undertakings through which the holding is effectively held:
  Please see the full chain of control in the ‘Chain of Control’ tab.
   
• Additional information: The disclosure obligation arose due to total holdings in voting rights for BlackRock, Inc. going above 5%.
   

3.  Further information 
This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations
Antje Witte 
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots 
T+32 2 559 92 64
laurent.schots@ucb.com    
 

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news